Clinical trial · Observational
A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea
A Post Marketing Surveillance on Lutathera® (Lutetium (177Lu) Oxodotreotide, 177Lu-DOTA0-Tyr3-Octreotate) in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) in Korea
NCT04946305CI-TRIAL-00079678completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Lutathera in patients with somatostatin receptor-positive GEP-NET in the real-world setting in Korea.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Somatostatin Receptor-positive GEP-NET | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lutathera | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Lutathera
- description
- Patients administered Lutathera by prescription
- interventionNames
- Other: Lutathera
Primary outcomes (2)
- measure
- Incidence of Adverse Events
- timeFrame
- Up to 36 weeks
- description
- Incidence of Adverse Events (AEs), Serious AE and unexpected AEs.
- measure
- Incidence of Adverse Drug Reactions
- timeFrame
- Up to 36 weeks
- description
- Incidence of Adverse Drug Reactions (ADRs), Serious ADRs and unexpected ADRs.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients who start Lutathera treatment per clinical judgment, according to the locally approved labeling. \- somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. 2. Patients who are willing to provide written informed consent. Exclusion Criteria: 1\. Patients with contraindication according to prescribing information for Lutathera in Korea.
References
Publications (0)
Data not yet available
No reference posted for this study.